

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:22:12 ON 27 SEP 2005

=> file caplus uspatful japio efull medline biosis embase scisearch
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.84 0.84

FILE 'CAPLUS' ENTERED AT 15:24:34 ON 27 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:24:34 ON 27 SEP 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:24:34 ON 27 SEP 2005

COPYRIGHT (C) 2005 Japanese Patent Office (JPO) - JAPIO

FILE 'EPFULL' ENTERED AT 15:24:34 ON 27 SEP 2005

COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 15:24:34 ON 27 SEP 2005

FILE 'BIOSIS' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

=> s mucositis and radiotherap? and (flavonoid# or isoflavonoid#)

L1 10 MUCOSITIS AND RADIOETHERAP? AND (FLAVONOID# OR ISOFLAVONOID#)

=> d l1 1-10 ibib abs

L1 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855814 CAPLUS

DOCUMENT NUMBER: 139:333152

TITLE: Curcumin combination for the prevention and/or treatment of tissue damage

INVENTOR(S): Rezvani, Mohiaddin

PATENT ASSIGNEE(S): Isis Innovation Limited, UK

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088986	A1	20031030	WO 2003-GB1694	20030416
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
GB 2387541	A1	20031022	GB 2002-8691	20020416
EP 1501526	A1	20050202	EP 2003-722760	20030416
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			GB 2002-8691	A 20020416
			GB 2002-18412	A 20020808
			WO 2003-GB1694	W 20030416

AB A combination of curcumin, an antioxidant, especially α -tocopherol, and at least one edible oil, especially sunflower oil, is useful in the prevention and/or treatment of tissue damage caused by non-phys. insult, especially **mucositis** or CNS damage caused by cancer therapy.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:84586 CAPLUS
 DOCUMENT NUMBER: 132:127742
 TITLE: Pharmaceutical composition in particular for preventing and treating **mucositis** induced by **radiotherapy** or chemotherapy comprising antiradical compounds
 INVENTOR(S): Besse, Jerome; Nguyen, Tham; Leyder, Joelle
 PATENT ASSIGNEE(S): Laboratoire L. Lafon, Fr.
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004878	A1	20000203	WO 1999-FR1760	19990719
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2781156	A1	20000121	FR 1998-9230	19980720
FR 2781156	B1	20010629		
CA 2337152	AA	20000203	CA 1999-2337152	19990719
AU 9946296	A1	20000214	AU 1999-46296	19990719
EP 1098631	A1	20010516	EP 1999-929503	19990719
EP 1098631	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521321	T2	20020716	JP 2000-560871	19990719
AT 235226	E	20030415	AT 1999-929503	19990719
PT 1098631	T	20030630	PT 1999-929503	19990719
ES 2196823	T3	20031216	ES 1999-929503	19990719
PRIORITY APPLN. INFO.:			FR 1998-9230	A 19980720
			WO 1999-FR1760	W 19990719

AB The invention concerns a pharmaceutical composition designed to adhere to a mucous membrane in particular for preventing or treating **radiotherapy**-related and chemotherapy-related **mucositis**, induced by **radiotherapy** or combined radiochemotherapy, comprising an efficient amount of an antiradical compound mixed with a vehicle which is liquid at room temperature and gels at the mucous membrane temperature and capable of adhering to the mucous membrane by its gelled state. A pharmaceutical composition for buccal mucosa contained hydrosol. rutoside 2-10, Poloxamer-407 14.0, HPMC 1-3, fragrance 0.1-0.5, and buffer for pH = 7 q.s. 100%.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 10 USPATFULL on STN
 ACCESSION NUMBER: 2003:283125 USPATFULL
 TITLE: Combination of bryostatin and paclitaxel for treating cancer
 INVENTOR(S): Schwartz, Gary K., Briarcliff Manor, NY, UNITED STATES
 Albino, Anthony P., New York, NY, UNITED STATES
 PATENT ASSIGNEE(S): Sloan - Kettering Institute for Cancer Research (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199469	A1	20031023
APPLICATION INFO.:	US 2002-215178	A1	20020807 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-137442, filed on 20 Aug 1998, GRANTED, Pat. No. US 6444638 Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, PENDING Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	5326		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 10 USPATFULL on STN
 ACCESSION NUMBER: 2003:271068 USPATFULL
 TITLE: Use of metabolic phenotyping in individualized treatment with amonafide
 INVENTOR(S): Leyland-Jones, Brian, Miami, FL, UNITED STATES
 PATENT ASSIGNEE(S): McGill University, Montreal, CANADA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003190671	A1	20031009
APPLICATION INFO.:	US 2002-124747	A1	20020416 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-87996, filed on 28 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271714P	20010228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	88	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	31 Drawing Page(s)	
LINE COUNT:	8446	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:200394 USPATFULL
TITLE: Use of metabolic phenotyping in individualized
treatment with amonafide
INVENTOR(S): Leyland-Jones, Brian, Miami, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138377	A1	20030724
APPLICATION INFO.:	US 2002-87996	A1	20020228 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271714P	20010228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	88	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	29 Drawing Page(s)	
LINE COUNT:	8181	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2001:123568 USPATFULL
TITLE: COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS
FOR TREATING CANCERS
INVENTOR(S): SCHWARTZ, GARY K., BRIARCLIFF MANOR, NY, United States
ALBINO, ANTHONY P., NEW YORK, NY, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011076	A1	20010802
	US 6444638	B2	20020903
APPLICATION INFO.:	US 1998-137442	A1	19980820 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, UNKNOWN Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	COOPER & DUNHAM, 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	5287		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for screening a modulating agent which
when combined with antitumor therapeutic agent increases apoptosis in
tumor cells. This invention also provides methods for screening
antitumor therapeutic agents suitable for combination therapy with a
protein kinase C inhibitors capable of potentiating apoptosis in tumor

cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 7 OF 10 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2001:140225 EPFULL
DATA UPDATE DATE: 20040303
DATA UPDATE WEEK: 200410
TITLE (ENGLISH): Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or **radiotherapy**
TITLE (FRENCH): L'acide lipoique pour la suppression des effets indesirables hematologiques dans la chimiotherapie et/ou **radiotherapie**
TITLE (GERMAN): Liponsaeure zur Vermeidung unerwunschter haematologischer Wirkungen in der Chemotherapie und/oder **Radiotherapie**
INVENTOR(S): Van Den Berg, Jeroen.J.M., Nassaulaan 21, NL-3971 HC Driebergen, NL; Osanto, Susanne., Prins Hendriklaan 10, NL-2341 JB Oegstgeest, NL; Hageman, Robert.J.J., Hamsterlaan 12, NL-6705 CT Wageningen, NL
PATENT APPLICANT(S): N.V. Nutricia, (Nutricia, N.V.), Postbus 1, 2700 MA Zoetermeer, NL
PATENT APPL. NUMBER: 923322
AGENT: van Westenbrugge, Andries, et al, Nederlandsch Octrooibureau P.O. Box 29720, 2502 LS The Hague, NL
AGENT NUMBER: 62593
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPA1 Application published with search report
PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1258243	A1	20021120
APPLICATION INFO.:	EP 2001-201835	A	20010516
PRIORITY INFO.:	EP 2001-201835	A	20010516 *

ABEN

The present invention is concerned with a method of suppressing the detrimental effects of chemotherapy and/or **radiotherapy** on a patient's health. More specifically the invention relates to a method comprising the administration of a special pharmaceutical or dietetic preparation containing lipoic acid and/or lipoic acid analogue in an effective amount to suppress the reduction in blood cell count resulting from chemotherapy and/or **radiotherapy**. The invention also relates to a pharmaceutical or dietetic preparation comprising: lipoic acid and/or lipoic acid analogue in an amount which is equivalent to 40-2000 mg R(+) lipoic acid; 0.2-60 μ moles intact protein; 200-800 mg vitamin C; 100-500 mg vitamin D; 200-1000 mgN-acetyl cystein and 5-100 mg zinc.

L1 ANSWER 8 OF 10 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1999:60773 EPFULL
DATA UPDATE DATE: 20040317
DATA UPDATE WEEK: 200412
TITLE (ENGLISH): PHARMACEUTICAL COMPOSITION IN PARTICULAR FOR PREVENTING AND TREATING **MUCOSITIS** INDUCED BY **RADIOOTHERAPY** OR **CHEMOTHERAPY**

TITLE (FRENCH): COMPOSITION PHARMACEUTIQUE DESTINEE NOTAMMENT A LA
PREVENTION ET AU TRAITEMENT DES RADIOMUCITES ET DES
CHIMIOMUCITES

TITLE (GERMAN): ARZNEIMITTEL INSBESONDERE ZUR VORBEUGUNG UND BEHANDLUNG
VON STRAHLUNGS- UND CHEMOMUKOSITIDEN

INVENTOR(S): BESSE, Jerome, Galenix Developpement-Europarc, 14, rue
Gustave Hertz, 33600 Pessac, FR; NGUYEN, Tham,
Laboratoire L. Lafon, 19, avenue du Professeur Cadiot,
94701 Maisons Alfort, FR; LEYDER, Jo[ille, Laboratoire
L. Lafon, 19, avenue du Professeur Cadiot, 94701
Maisons Alfort, FR

PATENT APPLICANT(S): LABORATOIRE L. LAFON, (L. LAFON, LABORATOIRE; LAFON,
LABORATOIRE L.), 19 Avenue du Professeur Cadiot, 94701
Maisons Alfort, FR

PATENT APPL. NUMBER: 212841

AGENT: Bernasconi, Jean Raymond, et al, c/o Cabinet Lavoix, 2,
Place d'Estienne d'Orves, 75441 Paris Cedex 09, FR

AGENT NUMBER: 13927

LANGUAGE OF FILING: French

LANGUAGE OF PUBL.: French

LANGUAGE OF PROCEDURE: French

LANGUAGE OF TITLE: German; English; French

DOCUMENT TYPE: Patent

PATENT INFO TYPE: EPB1 Granted patent .

PATENT INFORMATION:

	NUMBER	KIND	DATE
	NUMBER	KIND	DATE
	EP 1098631	B1	20030326
	WO 2000004878		20000203
DESIGNATED STATES:	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT		
	SE		
APPLICATION INFO.:	EP 1999-929503	A	19990719
	WO 1999-FR1760	A	19990719
PRIORITY INFO.:	FR 1998-9230	A	19980720
CITED PATENT LIT.:	EP 380367	A	
	EP 386960	A	
	EP 577143	A	
	EP 648496	A	
	WO 9321905	A	
	US 5281196	A	
	US 5858371	A	

L1 ANSWER 9 OF 10 MEDLINE on STN

ACCESSION NUMBER: 92194148 MEDLINE

DOCUMENT NUMBER: PubMed ID: 1800734

TITLE: Management of oral **mucositis** during local
radiation and systemic chemotherapy: a study of 98
patients.

AUTHOR: Carl W; Emrich L S

CORPORATE SOURCE: Roswell Park Memorial Institute, School of Dental Medicine,
Buffalo, N.Y.

SOURCE: Journal of prosthetic dentistry, (1991 Sep) 66 (3) 361-9.
Journal code: 0376364. ISSN: 0022-3913.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Dental Journals; Priority Journals

ENTRY MONTH: 199204

ENTRY DATE: Entered STN: 19920509
Last Updated on STN: 19920509

Entered Medline: 19920420

AB Oral **mucositis** is among the complications of head and neck irradiation and systemic chemotherapy. To determine whether or not **mucositis** could be prevented or reduced in intensity by using Kamilloosan Liquidum as an oral rinse, 98 patients were placed on study protocols. Twenty patients who were treated with radiation therapy and 46 patients who received systemic chemotherapy participated in prophylactic oral care with Kamilloosan oral rinse. Thirty-two patients were treated therapeutically after **mucositis** had developed. Sixteen patients receiving chemotherapy were treated therapeutically and prophylactically with Kamilloosan oral rinse during repeated cycles of chemotherapy. Only one of the 20 patients who had had radiation therapy developed grade 3 **mucositis** in the final week of treatment. Thirty-six of the 46 patients undergoing chemotherapy did not develop clinically noticeable **mucositis**. It appears that resolution of **mucositis** is accelerated by Kamilloosan rinse. Prophylactic oral care appeared to modify the oral environment favorably and maintain tissue integrity.

L1 ANSWER 10 OF 10 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004506331 EMBASE

TITLE: Dietary antioxidants and human cancer.

AUTHOR: Borek C.

CORPORATE SOURCE: Dr. C. Borek, Dept. of Comm. Hlth. and Fam. Med., Nutrition Infectious Disease Unit, Tufts University School of Medicine, Boston, MA 02111, United States.
carmia.borek@tufts.edu

SOURCE: Integrative Cancer Therapies, (2004) Vol. 3, No. 4, pp. 333-341.

Refs: 64

ISSN: 1534-7354 CODEN: ICTNAY

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 014 Radiology
016 Cancer
017 Public Health, Social Medicine and Epidemiology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20041217

Last Updated on STN: 20041217

AB Epidemiological studies show that a high intake of antioxidant-rich foods is inversely related to cancer risk. While animal and cell cultures confirm the anticancer effects of antioxidants, intervention trials to determine their ability to reduce cancer risk have been inconclusive, although selenium and vitamin E reduced the risk of some forms of cancer, including prostate and colon cancer, and carotenoids have been shown to help reduce breast cancer risk. Cancer treatment by radiation and anticancer drugs reduces inherent antioxidants and induces oxidative stress, which increases with disease progression. Vitamins E and C have been shown to ameliorate adverse side effects associated with free radical damage to normal cells in cancer therapy, such as **mucositis** and fibrosis, and to reduce the recurrence of breast cancer. While clinical studies on the effect of antioxidants in modulating cancer treatment are limited in number and size, experimental studies show that antioxidant vitamins and some phytochemicals selectively induce apoptosis in cancer cells but not in normal cells and prevent angiogenesis and metastatic spread, suggesting a potential role for antioxidants as adjuvants in cancer therapy.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:22:12 ON 27 SEP 2005

=> file caplus uspatful japio efull medline biosis embase scisearch
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.84 0.84

FILE 'CAPLUS' ENTERED AT 15:24:34 ON 27 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:24:34 ON 27 SEP 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:24:34 ON 27 SEP 2005

COPYRIGHT (C) 2005 Japanese Patent Office (JPO) - JAPIO

FILE 'EPFULL' ENTERED AT 15:24:34 ON 27 SEP 2005

COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 15:24:34 ON 27 SEP 2005

FILE 'BIOSIS' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright, (c) 2005 The Thomson Corporation

=> s mucositis and radiotherap? and (flavonoid# or isoflavonoid#)

L1 10 MUCOSITIS AND RADIOETHERAP? AND (FLAVONOID# OR ISOFLAVONOID#)

=> d l1 1-10 ibib abs

L1 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855814 CAPLUS

DOCUMENT NUMBER: 139:333152

TITLE: Curcumin combination for the prevention and/or treatment of tissue damage

INVENTOR(S): Rezvani, Mohiaddin

PATENT ASSIGNEE(S): Isis Innovation Limited, UK

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088986	A1	20031030	WO 2003-GB1694	20030416
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
GB 2387541	A1	20031022	GB 2002-8691	20020416
EP 1501526	A1	20050202	EP 2003-722760	20030416
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

PRIORITY APPLN. INFO.: GB 2002-8691 A 20020416
GB 2002-18412 A 20020808
WO 2003-GB1694 W 20030416

AB A combination of curcumin, an antioxidant, especially α -tocopherol, and at least one edible oil, especially sunflower oil, is useful in the prevention and/or treatment of tissue damage caused by non-phys. insult, especially mucositis or CNS damage caused by cancer therapy.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:84586 CAPLUS
 DOCUMENT NUMBER: 132:127742
 TITLE: Pharmaceutical composition in particular for preventing and treating **mucositis** induced by **radiotherapy** or chemotherapy comprising antiradical compounds
 INVENTOR(S): Besse, Jerome; Nguyen, Tham; Leyder, Joelle
 PATENT ASSIGNEE(S): Laboratoire L. Lafon, Fr.
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004878	A1	20000203	WO 1999-FR1760	19990719
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2781156	A1	20000121	FR 1998-9230	19980720
FR 2781156	B1	20010629		
CA 2337152	AA	20000203	CA 1999-2337152	19990719
AU 9946296	A1	20000214	AU 1999-46296	19990719
EP 1098631	A1	20010516	EP 1999-929503	19990719
EP 1098631	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521321	T2	20020716	JP 2000-560871	19990719
AT 235226	E	20030415	AT 1999-929503	19990719
PT 1098631	T	20030630	PT 1999-929503	19990719
ES 2196823	T3	20031216	ES 1999-929503	19990719
PRIORITY APPLN. INFO.:			FR 1998-9230	A 19980720
			WO 1999-FR1760	W 19990719

AB The invention concerns a pharmaceutical composition designed to adhere to a mucous membrane in particular for preventing or treating **radiotherapy**-related and chemotherapy-related **mucositis**, induced by **radiotherapy** or combined radiochemotherapy, comprising an efficient amount of an antiradical compound mixed with a vehicle which is liquid at room temperature and gels at the mucous membrane temperature and capable of adhering to the mucous membrane by its gelled state. A pharmaceutical composition for buccal mucosa contained hydrosol. rutoside 2-10, Poloxamer-407 14.0, HPMC 1-3, fragrance 0.1-0.5, and buffer for pH = 7 q.s. 100%.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:283125 USPATFULL
 TITLE: Combination of bryostatins and paclitaxel for treating cancer
 INVENTOR(S): Schwartz, Gary K., Briarcliff Manor, NY, UNITED STATES
 Albino, Anthony P., New York, NY, UNITED STATES
 PATENT ASSIGNEE(S): Sloan - Kettering Institute for Cancer Research (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199469	A1	20031023
APPLICATION INFO.:	US 2002-215178	A1	20020807 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-137442, filed on 20 Aug 1998, GRANTED, Pat. No. US 6444638 Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, PENDING Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	5326		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 10 USPATFULL on STN
 ACCESSION NUMBER: 2003:271068 USPATFULL
 TITLE: Use of metabolic phenotyping in individualized treatment with amonafide
 INVENTOR(S): Leyland-Jones, Brian, Miami, FL, UNITED STATES
 PATENT ASSIGNEE(S): McGill University, Montreal, CANADA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003190671	A1	20031009
APPLICATION INFO.:	US 2002-124747	A1	20020416 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-87996, filed on 28 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271714P	20010228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	88	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	31 Drawing Page(s)	
LINE COUNT:	8446	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:200394 USPATFULL
TITLE: Use of metabolic phenotyping in individualized
treatment with amonafide
INVENTOR(S): Leyland-Jones, Brian, Miami, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003138377	A1	20030724
APPLICATION INFO.:	US 2002-87996	A1	20020228 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271714P	20010228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	88	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	29 Drawing Page(s)	
LINE COUNT:	8181	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2001:123568 USPATFULL
TITLE: COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS
FOR TREATING CANCERS
INVENTOR(S): SCHWARTZ, GARY K., BRIARCLIFF MANOR, NY, United States
ALBINO, ANTHONY P., NEW YORK, NY, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011076	A1	20010802
	US 6444638	B2	20020903
APPLICATION INFO.:	US 1998-137442	A1	19980820 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, UNKNOWN Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	COOPER & DUNHAM, 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	5287		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for screening a modulating agent which
when combined with antitumor therapeutic agent increases apoptosis in
tumor cells. This invention also provides methods for screening
antitumor therapeutic agents suitable for combination therapy with a
protein kinase C inhibitors capable of potentiating apoptosis in tumor

cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 7 OF 10 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2001:140225 EPFULL
DATA UPDATE DATE: 20040303
DATA UPDATE WEEK: 200410
TITLE (ENGLISH): Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or **radiotherapy**
TITLE (FRENCH): L'acide lipoique pour la suppression des effets indesirables hematologiques dans la chimiotherapie et/ou **radiotherapie**
TITLE (GERMAN): Liponsaeure zur Vermeidung unerwunschter haematologischer Wirkungen in der Chemotherapie und/oder **Radiotherapie**
INVENTOR(S): Van Den Berg, Jeroen.J.M., Nassaulaan 21, NL-3971 HC Driebergen, NL; Osanto, Susanne., Prins Hendriklaan 10, NL-2341 JB Oegstgeest, NL; Hageman, Robert.J.J., Hamsterlaan 12, NL-6705 CT Wageningen, NL
PATENT APPLICANT(S): N.V. Nutricia, (Nutricia, N.V.), Postbus 1, 2700 MA Zoetermeer, NL
PATENT APPL. NUMBER: 923322
AGENT: van Westenbrugge, Andries, et al, Nederlandsch Octrooibureau P.O. Box 29720, 2502 LS The Hague, NL
AGENT NUMBER: 62593
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
LANGUAGE OF PROCEDURE: English
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPA1 Application published with search report
PATENT INFORMATION:

	NUMBER	KIND	DATE
	EP 1258243	A1	20021120
APPLICATION INFO.:	EP 2001-201835	A	20010516
PRIORITY INFO.:	EP 2001-201835	A	20010516 *

ABEN

The present invention is concerned with a method of suppressing the detrimental effects of chemotherapy and/or **radiotherapy** on a patient's health. More specifically the invention relates to a method comprising the administration of a special pharmaceutical or dietetic preparation containing lipoic acid and/or lipoic acid analogue in an effective amount to suppress the reduction in blood cell count resulting from chemotherapy and/or **radiotherapy**. The invention also relates to a pharmaceutical or dietetic preparation comprising: lipoic acid and/or lipoic acid analogue in an amount which is equivalent to 40-2000 mg R(+) lipoic acid; 0.2-60 μ moles intact protein; 200-800 mg vitamin C; 100-500 mg vitamin D; 200-1000 mgN-acetyl cystein and 5-100 mg zinc.

L1 ANSWER 8 OF 10 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1999:60773 EPFULL
DATA UPDATE DATE: 20040317
DATA UPDATE WEEK: 200412
TITLE (ENGLISH): PHARMACEUTICAL COMPOSITION IN PARTICULAR FOR PREVENTING AND TREATING **MUCOSITIS** INDUCED BY **RADIOOTHERAPY** OR CHEMOTHERAPY

TITLE (FRENCH): COMPOSITION PHARMACEUTIQUE DESTINEE NOTAMMENT A LA
PREVENTION ET AU TRAITEMENT DES RADIOMUCITES ET DES
CHIMIOMUCITES

TITLE (GERMAN): ARZNEIMITTEL INSBESONDERE ZUR VORBEUGUNG UND BEHANDLUNG
VON STRAHLUNGS- UND CHEMOMUKOSITIDEN

INVENTOR(S): BESSE, Jerome, Galenix Developpement-Europarc, 14, rue
Gustave Hertz, 33600 Pessac, FR; NGUYEN, Tham,
Laboratoire L. Lafon, 19, avenue du Professeur Cadiot,
94701 Maisons Alfort, FR; LEYDER, Jo[ille, Laboratoire
L. Lafon, 19, avenue du Professeur Cadiot, 94701
Maisons Alfort, FR

PATENT APPLICANT(S): LABORATOIRE L. LAFON, (L. LAFON, LABORATOIRE; LAFON,
LABORATOIRE L.), 19 Avenue du Professeur Cadiot, 94701
Maisons Alfort, FR

PATENT APPL. NUMBER: 212841

AGENT: Bernasconi, Jean Raymond, et al, c/o Cabinet Lavoix, 2,
Place d'Estienne d'Orves, 75441 Paris Cedex 09, FR

AGENT NUMBER: 13927

LANGUAGE OF FILING: French

LANGUAGE OF PUBL.: French

LANGUAGE OF PROCEDURE: French

LANGUAGE OF TITLE: German; English; French

DOCUMENT TYPE: Patent

PATENT INFO TYPE: EPB1 Granted patent

PATENT INFORMATION:

PATENT INFORMATION:

NUMBER	KIND	DATE
NUMBER	KIND	DATE

EP 1098631	B1	20030326
------------	----	----------

DESIGNATED STATES:	WO 2000004878	20000203
APPLICATION INFO.:	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT	
	SE	
PRIORITY INFO.:	EP 1999-929503	A 19990719
CITED PATENT LIT.:	WO 1999-FR1760	A 19990719
	FR 1998-9230	A 19980720
	EP 380367	A
	EP 386960	A
	EP 577143	A
	EP 648496	A
	WO 9321905	A
	US 5281196	A
	US 5858371	A

L1 ANSWER 9 OF 10 MEDLINE on STN

ACCESSION NUMBER: 92194148 MEDLINE

DOCUMENT NUMBER: PubMed ID: 1800734

TITLE: Management of oral **mucositis** during local
radiation and systemic chemotherapy: a study of 98
patients.

AUTHOR: Carl W; Emrich L S

CORPORATE SOURCE: Roswell Park Memorial Institute, School of Dental Medicine,
Buffalo, N.Y.

SOURCE: Journal of prosthetic dentistry, (1991 Sep) 66 (3) 361-9.
Journal code: 0376364. ISSN: 0022-3913.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Dental Journals; Priority Journals

ENTRY MONTH: 199204

ENTRY DATE: Entered STN: 19920509
Last Updated on STN: 19920509

Entered Medline: 19920420

AB Oral **mucositis** is among the complications of head and neck irradiation and systemic chemotherapy. To determine whether or not **mucositis** could be prevented or reduced in intensity by using Kamilloosan Liquidum as an oral rinse, 98 patients were placed on study protocols. Twenty patients who were treated with radiation therapy and 46 patients who received systemic chemotherapy participated in prophylactic oral care with Kamilloosan oral rinse. Thirty-two patients were treated therapeutically after **mucositis** had developed. Sixteen patients receiving chemotherapy were treated therapeutically and prophylactically with Kamilloosan oral rinse during repeated cycles of chemotherapy. Only one of the 20 patients who had had radiation therapy developed grade 3 **mucositis** in the final week of treatment. Thirty-six of the 46 patients undergoing chemotherapy did not develop clinically noticeable **mucositis**. It appears that resolution of **mucositis** is accelerated by Kamilloosan rinse. Prophylactic oral care appeared to modify the oral environment favorably and maintain tissue integrity.

L1 ANSWER 10 OF 10 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004506331 EMBASE

TITLE: Dietary antioxidants and human cancer.

AUTHOR: Borek C.

CORPORATE SOURCE: Dr. C. Borek, Dept. of Comm. Hlth. and Fam. Med., Nutrition Infectious Disease Unit, Tufts University School of Medicine, Boston, MA 02111, United States.
carmia.borek@tufts.edu

SOURCE: Integrative Cancer Therapies, (2004) Vol. 3, No. 4, pp. 333-341.

Refs: 64

ISSN: 1534-7354 CODEN: ICTNAY

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 014 Radiology
016 Cancer
017 Public Health, Social Medicine and Epidemiology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20041217

Last Updated on STN: 20041217

AB Epidemiological studies show that a high intake of antioxidant-rich foods is inversely related to cancer risk. While animal and cell cultures confirm the anticancer effects of antioxidants, intervention trials to determine their ability to reduce cancer risk have been inconclusive, although selenium and vitamin E reduced the risk of some forms of cancer, including prostate and colon cancer, and carotenoids have been shown to help reduce breast cancer risk. Cancer treatment by radiation and anticancer drugs reduces inherent antioxidants and induces oxidative stress, which increases with disease progression. Vitamins E and C have been shown to ameliorate adverse side effects associated with free radical damage to normal cells in cancer therapy, such as **mucositis** and fibrosis, and to reduce the recurrence of breast cancer. While clinical studies on the effect of antioxidants in modulating cancer treatment are limited in number and size, experimental studies show that antioxidant vitamins and some phytochemicals selectively induce apoptosis in cancer cells but not in normal cells and prevent angiogenesis and metastatic spread, suggesting a potential role for antioxidants as adjuvants in cancer therapy.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	44.71	45.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

FILE 'STNGUIDE' ENTERED AT 15:33:08 ON 27 SEP 2005
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Sep 23, 2005 (20050923/UP).

Basic Search

[Advanced Search](#) [Search Preferences](#)

(flavonoids or isoflavonoids) and gel

Search

☒ Journal sources
 ☒ Preferred Web sources
 ☒ Other Web sources
 ☐ Exact phrase
Searched for:: :All of the words:(**flavonoids or isoflavonoids**) and gelFound:: :8,758 total | [4,245 journal results](#) | [1,411 preferred web results](#) | [3,102 other web res](#)Sort by:: :[relevance](#) | [date](#)

Save checked results



Email checked results

Export checked results

- ☐ **41. ASSESSMENT OF THE IN VIVO ANTIOXIDANT POTENTIAL OF WILD BLUEBERRIES IN HUMANS** [PDF-267K]
 Jan 2005
 ...METABOLISM & PHARMACOKINETICS OF ANTHOCYANINS/**FLAVONOIDS** 10 IDEOLOGY...13 Absorption of **Flavonoids**...19 Metabolism and Pharmacokinetics of **Flavonoids** 20 Metabolism and...
 [http://www.uoguelph.ca/hb+ns/Theses/KayPhDThesis.pdf]
[similar results](#)
- ☐ **42. Prenylated flavonoids from Maclura pomifera**
Lee, S.-J. / Wood, A.R. / Maier, C.G.-A. / Dixon, R.A. / Mabry, T.J.,
Phytochemistry, Dec 1998
 ...front mdner PRENYLATED **FLAVONOIDS** FROM MACLURA POMIFERA...pomifera Moraceae prenylated **flavonoids** prenylated isoflavo Abstract-Eight prenylated **flavonoids**, including three new compounds...chromatography on silica **gel** and sAuthor to whom correspondence...
Full text article available from **SCIENCE DIRECT**
[similar results](#)
- ☐ **43. Comprehensive Nutrient Review: Apigenin Research Abstracts** [101K]
 Nov 2004
 ...verbascoside) and isoacteoside, along with the **flavonoids** luteolin and apigenin are major components...Lett. 2002 Feb 8176(1):1723. Effect of **flavonoids** on cell cycle progression in prostate...Yamagata 9909585, Japan. The effect of some **flavonoids**, which are components of fruits, vegetables...
 [http://www.lef.org/abstracts/codex/apigenin_abstracts....]
[similar results](#)
- ☐ **44. Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women -- Moon et al. 279 (2): ... [105K]**
Terao, J, Jan 2005
 ...QUERCETIN IS ONE OF THE ABUNDANT flavonol-type **flavonoids**, commonly found in vegetables and fruits (12 15). The average daily intake of **flavonoids**, including three flavonol-type **flavonoids** (quercetin, myricetin, kaempferol) and two...
 [http://ajpregu.physiology.org/cgi/content/full/279/2/R...]

 Re
 us
 fol
 an
 an
 an
 bio
 bio
 gly
 in
 lute
 me
 nm
 oxi
 pla
 pro
 sec
 Or
 Al
 F

[similar results](#)

- ❑ **45. [example of longevity related medline abstracts -\(long!\) \[42K\]](#)**
 Oct 2004
 ...by using the single-cell **gel** electrophoresis assay (comet...protective than the conjugated **flavonoids** (eg, quercetin compared with...antioxidant activity of free **flavonoids** is related to the number...47, 1997. Abstract Thirteen **isoflavonoids**, **flavonoids**, and lignans, including some...
[\[http://www.cryonet.org/cgi-bin/dsp.cgi?msg=11859\]](http://www.cryonet.org/cgi-bin/dsp.cgi?msg=11859)
[similar results](#)
- ❑ **46. [Brazilian Journal of Medical and Biological Research - Antioxidant properties of natural compounds used in popular medicine ... \[59K\]](#)**
M.G. Repetto / S.F. Llesuy, Jan 2005
 ...phenolic antioxidants such as **flavonoids**, tannins, coumarins, xanthenes...adherent and transparent **gel** formed by 95% water and 5...barrier depend not only on the **gel** structure but also on the...triterpene glycoside glycyrrhizin, **flavonoids** (liquiritin and isoliquiritin), **isoflavonoids** (isoflavonol, kumatakenin...
[more hits from \[http://www.scielo.br/scielo.php?script=sci_arttext&pid...\]](http://www.scielo.br/scielo.php?script=sci_arttext&pid...)
[similar results](#)
- ❑ **47. [Corsifurans A-C, 2-arylbenzofurans of presumed stilbenoid origin from Corsinia coriandrina \(Hepaticae\)](#)**
von Reusz, S.H. / Konig, W.A., *Phytochemistry*, Dec 2004
 ...In comparison to **flavonoids** (2), **isoflavonoids** (3) and stilbenoids...chromatographed on silica **gel** 60 F 254 (Merck) using...plates with silica **gel** 60 F 254 (Merck) using...Antimicrobial and antioxidant **flavonoids** from the root wood...
Full text article available from  **ScienceDirect**
[similar results](#)
- ❑ **48. [COSMETIC COMPOSITION FOR PREVENTING AND/OR CORRECTING THE FUNCTIONAL DISORDERS OF THE PILO-SEBACEOUS UNIT OF MAMMALS](#)**
DURANTON, Albert / MALNOE, Armand / L' OREAL, *PATENT COOPERATION TREATY APPLICATION*, Apr 2004
 ...from the vine and tea. 25 The **isoflavonoids** constitute a sub-class of the **flavonoids**. They are I formed of a 3-phenylchromane...of oxidation. Contrary to the **flavonoids**, the **isoflavonoids** are present in only a very limited...Isoflavonoids" of the 5 monograph "The **Flavonoids**" (Dewick, P.M. Harbone Ed. pp. 125-157 (1 988)). **Isoflavonoids** particularly suited to being implemented...
Full text available at patent office. For more in-depth searching go to  **LexisNexis**
[similar results](#)
- ❑ **49. [United States Patent: 5,733,759 \[75K\]](#)**
 Jul 2002
 ...Tunen, "F1 hybrid seed production and **flavonoids**," *Prophyta*, Jun. 1992, pp. 56-58. Primary...in post-dispersal pollen function. **Flavonoids** are an abundant class of small molecular...violet plant colors. Other pigmented **flavonoids**, the chalcones, and some flavonols and...
[\[http://wsurf5.respark.wsu.edu/US%20Issued%20Patents%20...\]](http://wsurf5.respark.wsu.edu/US%20Issued%20Patents%20...)
[similar results](#)
- ❑ **50. [Expression of a putative flavonoid 3'-hydroxylase in sorghum mesocotyls synthesizing 3-deoxyanthocyanidin phytoalexins](#)**
Boddu, J. / Svabek, C. / Sekhon, R. / Gevens, A. / Nicholson, R.L. / Jones, A.D. / Pedersen, J.F. / (...) / Chopra, S., *Physiological and Molecular Plant Pathology*, Aug 2004
 ...ofchs,f3'h, anddfrgenes in sorghum. RNA **gel** blots were prepared from total RNA...importance as a molecular genetic system, **flavonoids** are involved in various biological...as explained below. 2.2 DNA and RNA **gel** blot hybridizations Plant genomic DNA...

Full text article available from  SCIENCE DIRECT

[similar results](#)

- ☐ 51. [Plant cell factories in the post-genomic era: new ways to produce designer secondary metabolites](#)

Oksman-Caldentey, K.-M. / Inze, D., *Trends in Plant Science*, Sep 2004

...terpenoids), alkaloids, phenylpropanoids and **flavonoids**. The polyketides are produced via the...acids phenylalanine or tyrosine and the **flavonoids** are synthesized by the combination of...certain plant families. By contrast, **flavonoids** are abundant in many plant species...

Full text article available from  SCIENCE DIRECT

[similar results](#)

- ☐ 52. [No Job Name](#) [PDF-25K]

Apr 2005

...potencies among these and other common **flavonoids**. The flavones kaempferol and dihydroquer...by column chromatography using silica **gel** with hexane/ethyl acetate (80:20) to...phytotoxicity of catechins and other **flavonoids**: flavonoid conversions by cell-free protein...

[more hits from](#) [http://crb.colostate.edu/home/Assets/papers/Ravi2004.p...]

[similar results](#)

- ☐ 53. [Antibacterial property of isoflavonoids isolated from Erythrina variegata against cariogenic oral bacteria](#)

Sato, M. / Tanaka, H. / Fujiwara, S. / Hirata, M. / Yamaguchi, R. / Etoh, H. / Tokuda, C., *Phytomedicine*, Jan 2003

...Leguminosae) by repeated silica **gel** column chromatography, against...words Cariogenic bacteria **isoflavonoids** antibacterial activity Erythrina...Havsteen, 1983 B. Havsteen **Flavonoids**, a class of natural products...Z. Khan M. Anwar Three new **isoflavonoids** from Erythrina variegata Heterocycles...

Full text article available from  SCIENCE DIRECT

[similar results](#)

- ☐ 54. [Measuring educational gains and setting consequences charter schooling and the no child left behind policy /](#)

Lyttle, Erin., Jan 2004

Thesis (M.A.)--Duquesne University, 2004. Title from document title page. Abstract included in electronic submission form. Includes bibliographical references (p. 81-85) and abstract.

Full text thesis available via NDLTD

[similar results](#)

- ☐ 55. [Learning to create : a collection of personal essays /](#)

1973- Christiansen, Naomi Lund., Jan 2004

Thesis (M.A.)--Brigham Young University. Dept. of English, 2004. Includes bibliographical references.

Full text thesis available via NDLTD

[similar results](#)



- ☐ 56. [Biotransformation of soy isoflavone-glycosides in laying hens: intestinal absorption and preferential accumulation into...](#)


Saitoh, S. / Sato, T. / Harada, H. / Matsuda, T., *Biochimica et Biophysica Acta (BBA)/General Subjects*, Sep 2004

...All of the serum and yolk fractions were subjected to protein composition analysis by sodium dodecyl sulfate-polyacrylamide **gel** electrophoresis (SDS-PAGE) according to Laemmli's method [27] and isoflavone quantitative analysis. 2.8 Statistics Data are presented...

Full text article available from  SCIENCE DIRECT

[similar results](#)

- ☐ **57.** [Bioreduction of hexavalent chromium flow-through column experiments and reactive transport modeling /](#)
1970- Alam, Md Mahbub,, Jan 2004
 Thesis (Ph. D. in Civil Engineering)--Washington State University. Includes bibliographical references.
Full text thesis available via ND LTD
[similar results](#)
- ☐ **58.** [Kaempferol blocks oxidative stress in cerebellar granule cells and reveals a key role for reactive oxygen species...](#)
Samhan-Arias, A.K. / Martin-Romero, F.J. / Gutierrez-Merino, C., *Free Radical Biology and Medicine*, Jul 2004
 ...this redox chain [24,27] . **Flavonoids** constitute a group of polyphenolic...ubiquinone (0.06-0.1 V) [31] . As **flavonoids** are also lipophilic compounds...tested the hypothesis that some **flavonoids** could be interfering with...electrophoresis in a 1.2% agarose-TBE gel. NADH oxidase activity NADH...
Full text article available from 
[similar results](#)
- ☐ **59.** [Virginia Bioinformatics Institute - Project Summary \[8K\]](#)
 May 2005
 ...SRNF). It is a rich source of natural products, such as **flavonoids**, **isoflavonoids** and triterpenes, which impact its properties as a forage...program) ii) protein expression patterns using two-dimensional **gel** electrophoresis and mass spectrometry (MALDI-TOF and Q-TOF...
[more hits from \[http://research.vbi.vt.edu/article/articleprint/133/-1...\]](http://research.vbi.vt.edu/article/articleprint/133/-1...)
[similar results](#)
- ☐ **60.** [Agrobacterium-mediated transformation in the high-value medicinal plant Echinacea purpurea](#)
Wang, H.-M. / To, K.-Y., *Plant Science*, Apr 2004
 ...classes (flavonols, flavones, **isoflavonoids**, and anthocyanins) of **flavonoids**. **Flavonoids** are a large class of plant...fruits, seeds, and leaves, **flavonoids** also play key roles in...product was run on 1% agarose **gel**.). The expression vector...
Full text article available from 
[similar results](#)



Results Pages: [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [[Next >>](#)] [back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2005

Basic Search

[Advanced Search](#) [Search Preferences](#)

(flavonoids or isoflavonoids) and gel



Search

☒ Journal sources
 ☒ Preferred Web sources
 ☒ Other Web sources
 ☐ Exact phrase
Searched for:: :All of the words:(**flavonoids or isoflavonoids**) and gelFound:: :**8,758 total** | **4,245 journal results** | **1,411 preferred web results** | **3,102 other web res**Sort by:: :**relevance** | [date](#)

Save checked results






Email checked results

Export checked results

- ☐ 1. [Flavonoids and isoflavonoids from *Genista morisii*](#)
Giachi, I. / Manunta, A. / Morelli, I. / Pistelli, L., *Biochemical Systematics and Ecology*, Aug 2002
 ...01)00116-8 **Flavonoids** and **isoflavonoids** from *Genista morisii* Isa...*Genista morisii* Leguminosae **Flavonoids Isoflavonoids** Chemotaxonomy 1 Subject...*Genista* is known to contain **flavonoids** as well as lupine-type quinolizidine...C 11 were applied to Si **gel** column chromatography eluted...
Full text article available from  **similar results**
- ☐ 2. [Two prenylated flavonoids from the stem bark of *Erythrina burttii*](#)
Yenesew, A. / Irungu, B. / Derese, S. / Midiwo, J.O. / Heydenreich, M. / Peter, M.G., *Phytochemistry*, Jun 2003
 ...**flavonoids** and **isoflavonoids**. Some of the flavanones...have reported new **flavonoids** and **isoflavonoids** from the stem...plant three known **isoflavonoids** were also isolated...coated silica **gel** 60 F 254 plates. CC on silica **gel** 60 (70-230 mesh...
Full text article available from  **similar results**
- ☐ 3. [Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport -- Zhang and Morris ... \[136K\]](#)
Zhang, S / Shuzhong Zhang / Marilyn E. Morris , Oct 2004
 ...March 2003 Effects of the **Flavonoids** Biochanin A, Morin, Phloretin...Results Discussion References **Flavonoids** are constituents of fruits...was incubated with 100 μ M **flavonoids**, or solvent control (0.2...a 7.5% SDS-polyacrylamide **gel** electrophoresis. Gels were...
 [http://jpet.aspetjournals.org/cgi/content/full/304/3/1...] **similar results**
- ☐ 4. [Mass spectrometric methods for the determination of flavonoids in biological samples](#)
Prasain, J.K. / Wang, C.-C. / Barnes, S., *Free Radical Biology and Medicine*, Nov 2004
 ...There are certain hydroxyl groups in **flavonoids** that are usually glycosylated. These...with the adjacent carbonyl at C-4. **Isoflavonoids** are **flavonoids** with ring B attached to the C-3...of the heterocyclic ring of the **isoflavonoids** can occur [27] . **Flavonoids** are converted to several other phenolic...

 Re
us
fo
an
an
an
bio
bio
gly
in
lut
me
nm
oxi
pla
pro
sec
Or
Al
f

Full text article available from  [similar results](#)

- ☐ 5. Isoflavonoids from Dalbergia olivari
Ito, C. / Itoigawa, M. / Kanematsu, T. / Ruangrunsi, N. / Mukainaka, T. / Tokuda, H. / Nishino, H. / Furukawa, H., *Phytochemistry*, Dec 2003
 ...Japan, Gifu, March, 2000. **Isoflavonoids** from Dalbergia olivari Chihiro...subjected successively to silica **gel** column chromatography and...Dewick, 1988 Dewick P.M. **Isoflavonoids** Harborne J.B. The **Flavonoids**, Chapter 5 1988 125 209...1976 Ingham J.L. Induced **isoflavonoids** from fungus-infected stems...
 Full text article available from  [similar results](#)
- ☐ 6. Biological activity of five antibacterial flavonoids from Combretum erythrophyllum (Combretaceae)
Martini, N.D. / Katerere, D.R.P. / Eloff, J.N., *Journal of Ethnopharmacology*, Aug 2004
 ...activity of five antibacterial **flavonoids** from Combretum erythrophyllum...and closed column Silica **gel** chromatography and collected...chickpea (Ibrahim, 2000). **Flavonoids** have been reported to be...selectively inhibited by **flavonoids** and **isoflavonoids** derived from plants. Basile...
 Full text article available from  [similar results](#)
- ☐ 7. NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS
WONG, Norman / TUCKER, Joe / MCCAFFREY, David, Robert / RESVERLOGIX CORP., PATENT COOPERATION TREATY APPLICATION, Apr 2005
 ...field of synthesis and administration of **flavonoids** and derivatives thereof suitable for...molecule. STILBENES, POLYPHENOLS AND **FLAVONOIDS** AS ANTI-OXIDANTS Reactive oxygen species...the ROS. Stilbenes, polyphenols and **flavonoids** all contain at least two phenolic ring...
 Full text available at patent office. For more in-depth searching go to  [similar results](#)
- ☐ 8. Prenylated flavonoids from Deguelia hatschbachii and their systematic significance in Deguelia
Magalhaes, A.F. / Tozzi, A.M.G.A. / Magalhaes, E.G. / Moraes, V.R.S., *Phytochemistry*, May 2001
 ...compounds furnished by Deguelia species **Flavonoids Isoflavonoids** Stilbene Chalcone Flavanone Isoflavanone...Contents (mg/g of roots) Extract **Flavonoids** Petrol Dichloromethane 1 nd b 12...b nd=not detected.). Thus the **flavonoids** of D. hatschbachii mainly consist of **isoflavonoids**, as observed for the Deguelia species...
 Full text article available from  [similar results](#)
- ☐ 9. Flavonoids from the stem bark of Bolusanthus speciosus
Bojase, G. / Wanjala, C.C.W. / Majinda, R.R.T., *Phytochemistry*, Apr 2001
 ...speciosus revealed the presence of **isoflavonoids** (Ascres et al., 1985). From methanolic...stem bark of B. speciosus , three new **isoflavonoids** were isolated and characterization of...vacuum liquid chromatography- silica **gel** HF 254 5-15 mu m mesh (Merck) Sephadex...
 Full text article available from  [similar results](#)
- ☐ 10. Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells
O'Prey, J. / Brown, J. / Fleming, J. / Harrison, P.R., *Biochemical Pharmacology*, Dec

2003

...00593-8 Elsevier Inc. Effects of dietary **flavonoids** on major signal transduction pathways...Bearsden, Glasgow G61 1BD, Scotland, UK **Flavonoids** (FVs) are an important class of plant...levels, various naturally-occurring **flavonoids** have been shown to be cancer-protective...

Full text article available from  SCIENCE @ DIRECT

[similar results](#)

11. Prenylated flavonoids from *Moghania philippinensis*

Ahn, E.-M. / Nakamura, N. / Akao, T. / Komatsu, K. / Qui, M.-H. / Hattori, M., *Phytochemistry*, Dec 2003

...of China Five prenylated **flavonoids**, 8-(1,1-dimethylallyl)genistein...chemical means. Five prenylated **flavonoids** were isolated from the roots...regard chemical constituents, **isoflavonoids**, prenylated **flavonoids**, flemiphilippinins A, B...Sephadex LH-20 and silica gel to give five new compounds...

Full text article available from  SCIENCE @ DIRECT

[similar results](#)

12. CHERRY EXTRACTS FOR INHIBITING CYCLOOXYGENASE ENZYMES

NAIR, Muraleedharan, G. / WANG, Haibo / STRASBURG, Gale, M. / BOOREN, Alden, M. / GRAY, James, I. / MICHIGAN STATE UNIVERSITY, EUROPEAN PATENT, Oct 2001

...effect of PGHS-1 (COX-1) by **flavonoids** and **isoflavonoids** at 200 µm concentrations...PGHS- 1 enzyme (COX-1) by **flavonoids** from BALATON tart cherries...PGHS-1 enzyme (COX-1) by **isoflavonoids** from BALATON tart cherries...further purified by silica gel vacuum liquid chromatography...

Full text available at patent office. For more in-depth searching go to  LexisNexis

[similar results](#)

13. Sulfation of Flavonoids and Other Phenolic Dietary Compounds by the Human Cytosolic Sulfotransferases

Pai, T.G. / Suikō, M. / Sakakibara, Y. / Liu, M.-C., *Biochemical and Biophysical Research Communications*, Aug 2001

...sulfate-polyacrylamide gel electrophoresis. Sulfation...has focused attention on **flavonoids**, **isoflavonoids**, and other phenolic dietary...sulfation of representative **flavonoids**, **isoflavonoids**, anti-oxidants, and other...high activity with the **flavonoids** but not with the **isoflavonoids**. SULT1C ST #2 showed high...

Full text article available from  SCIENCE @ DIRECT

[similar results](#)

14. Characterization of O-methyltransferase ScOMT1 cloned from *Streptomyces coelicolor* A3 (2)

Yoon, Y. / Yi, Y.S. / Lee, Y. / Kim, S. / Kim, B.G. / Ahn, J.H. / Lim, Y., *BBA - Gene Structure and Expression*, Aug 2005

...affinity chromatography. SDS-PAGE gel was stained with Coomassie...vivo and in vitro analysis of **flavonoids** and related compounds using...nutrients to the residents[1].

Flavonoids are one of the compounds found...bacteria[1,2]. In addition, since **flavonoids** contain 15-carbon which forms...

Full text article available from  SCIENCE @ DIRECT

[similar results](#)

15. Differential interaction of *Sophora* isoflavonoids with lipid bilayers

Hendrich, A.B. / Malon, R. / Pola, A. / Shirataki, Y. / Motohashi, N. / Michalak, K., *European Journal of Pharmaceutical Sciences*, Aug 2002

...compounds are **flavonoids** or **isoflavonoids** differing mainly in...the interactions of **flavonoids** or **isoflavonoids** with lipid membranes...The values of the gel-liquid crystalline...decreasing of the lipid gel-liquid crystalline...results obtained for **flavonoids** other than those studied...

Full text article available from  SCIENCE DIRECT

[similar results](#)

16. [7a-O-methyldequelol, a modified rotenoid with an open ring-C, from the roots of *Derris trifoliata*](#)
Yenesew, A. / Mushibe, E.K. / Induli, M. / Derese, S. / Midiwo, J.O. / Kabaru, J.M. / Heydenreich, M. / (...) / Peter, M.G., *Phytochemistry*, Mar 2005
 ...et al., 1989 E. Dagne A. Yenesew P.G. Waterman **Flavonoids** and **isoflavonoids** from *Tephrosia fulvinervis* and *Tephrosia pentaphylla*...1994 P.M. Dewick **Isoflavonoids** J.B. Harborne **Flavonoids: advances in research since 1986** 1994 Chapman...

Full text article available from  SCIENCE DIRECT

[similar results](#)

17. [Comparative phytochemical analysis of four Mexican *Nymphaea* species](#)
Marquina, S. / Bonilla-Barbosa, J. / Alvarez, L., *Phytochemistry*, Apr 2005
 ...1999), as well as two rare macrocyclic **flavonoids** from *N. lotus* (Elegami et al., 2003...EtOAc (85:15), was applied to a silica **gel** CC (400 g) eluted with a gradient mixture...hexane-EtOAc (1:1) was subjected to silica **gel** CC, eluted with CH₂Cl₂ - MeOH (gradient...

Full text article available from  SCIENCE DIRECT

[similar results](#)

18. [Identification of a novel zebrafish SULT1 cytosolic sulfotransferase: cloning, expression, characterization, and...](#)
Ming-Yih Liu / Yuh-Shyong Yang / Takuya Sugahara / Shin Yasuda / Ming-Cheh Liu, *Arch Biochem Biophys*, May 2005
 ...35kDa protein upon sodium dodecyl sulfate-polyacrylamide **gel** electrophoresis. Among the endogenous compounds tested as...activities toward a number of xenobiotics including some **flavonoids**, **isoflavonoids**, and other phenolic compounds, with a pH optimum at 7.0...

MEDLINE/PubMed Citation on  PubMed

[similar results](#)

19. [Flavonoids and isoflavonoids from *Tephrosia fulvinervis* and *Tephrosia pentaphylla*](#)
Dagne, E. / Yenesew, A. / Waterman, P.G., *Phytochemistry*, Jan 1989
 ...for elaborating **flavonoids** and **isoflavonoids** [1]. As part of...to be rich in **flavonoids**. It proved possible...extracted with petrol **Flavonoids** of *Tephrosia* 3209...graphy over silica **gel** eluting with petrol...PTLC on silica **gel** (solvent: C₆H₆...

Full text article available from  SCIENCE DIRECT

[similar results](#)

20. [Contexts for Facilitating Emergent Literacy in Typically Developing Preschoolers](#)
Wilhjelm, Karen Nicole, Apr 2004
 The purpose of this study was to investigate if there is an additive benefit in training Emergent Literacy (EL) skills with typically developing preschoolers using a combined intervention approach, Dialogic Reading (DR) plus classroom Phonological ...

Full text thesis available via NDLTD

[similar results](#)



Results Pages: [[<<](#) [Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [[Next](#) [>>](#)] [back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)
[Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

Powered by FAST © Elsevier 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul53cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:14:51 ON 27 SEP 2005

=> file caplus uspatfull eptfull medline japio biosis embase scisearch
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 16:15:19 ON 27 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:15:19 ON 27 SEP 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EPTFULL' ENTERED AT 16:15:19 ON 27 SEP 2005

COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 16:15:19 ON 27 SEP 2005

FILE 'JAPIO' ENTERED AT 16:15:19 ON 27 SEP 2005

COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'BIOSIS' ENTERED AT 16:15:19 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:15:19 ON 27 SEP 2005

Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:15:19 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

=> Gel? and (isoflavonoid? or flavonoid?)

GEL? IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s Gel? and (isoflavonoid? or flavonoid?)

L1 6275 GEL? AND (ISOFLAVONOID? OR FLAVONOID?)

=> s l1 and sol(w)gel

L2 42 L1 AND SOL(W) GEL

=> s l2 and (poloxamer? or poloxamine? or divinylbenzenesorbitol)

L3 5 L2 AND (POLOXAMER? OR POLOXAMINE? OR DIVINYLBENZENESORBITOL)

=> s l3 and (rutoside or diosmin or quercitin or tangeretin or hesperidin or genistein or daidzin or glycitin or rutin)

L4 0 L3 AND (RUTOSIDE OR DIOSMIN OR QUERCITIN OR TANGERETIN OR HESPERIDIN OR GENISTEIN OR DAIDZIN OR GLYCITIN OR RUTIN)

=> d l3 1-5 ibib abs

L3 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2004:95506 USPATFULL

TITLE: Multiblock biodegradable hydrogels for drug delivery and tissue treatment

INVENTOR(S): Pathak, Chandrashekhara P., Austin, TX, UNITED STATES
Barman, Shikha P., Bedford, MA, UNITED STATES
Philbrook, C. Michael, Boston, MA, UNITED STATES
Sawhney, Amarpreet S., Lexington, MA, UNITED STATES
Coury, Arthur J., Boston, MA, UNITED STATES
Avila, Luis Z., Arlington, MA, UNITED STATES
Kieras, Mark T., Burlingame, CA, UNITED STATES

PATENT ASSIGNEE(S): Focal, Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004072961	A1	20040415
	US 6923986	B2	20050802
APPLICATION INFO.:	US 2003-650163	A1	20030827 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-114722, filed on 2 Apr 2002, GRANTED, Pat. No. US 6639014 Continuation of Ser. No. US 2000-710416, filed on 9 Nov 2000, GRANTED, Pat. No. US 6410645 Division of Ser. No. US 1996-692914, filed on 26 Jul 1996, GRANTED, Pat. No. US 6201065		

NUMBER

DATE

 PRIORITY INFORMATION: US 1995-1723P 19950728 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: GENZYME CORPORATION C/O HOLLAND & KNIGHT, LLP, HOLLAND
 & KNIGHT, LLP, ONE ATLANTIC CENTER, 1201 WEST PEACHTREE
 STREET, N.E., ATLANTA, GA, 30309-3400
 NUMBER OF CLAIMS: 50
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 8 Drawing Page(s)
 LINE COUNT: 1475
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Gel-forming macromers including at least four polymeric
 blocks, at least two of which are hydrophobic and at least one of which
 is hydrophilic, and including a crosslinkable group are provided. The
 macromers can be covalently crosslinked to form a **gel** on a
 tissue surface in vivo. The **gels** formed from the macromers
 have a combination of properties including thermosensitivity and
 lipophilicity, and are useful in a variety of medical applications
 including drug delivery and tissue coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2002:273521 USPATFULL
 TITLE: Multiblock biodegradable hydrogels for drug delivery
 and tissue treatment
 INVENTOR(S): Pathak, Chandrashekhar P., Austin, TX, UNITED STATES
 Barman, Shikha P., Bedford, MA, UNITED STATES
 Philbrook, C. Michael, Boston, MA, UNITED STATES
 Sawhney, Amarpreet S., Lexington, MA, UNITED STATES
 Coury, Arthur J., Boston, MA, UNITED STATES
 Avila, Luis Z., Arlington, MA, UNITED STATES
 Kieras, Mark T., Menlo Park, CA, UNITED STATES
 PATENT ASSIGNEE(S): Focal, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151650	A1	20021017
	US 6639014	B2	20031028
APPLICATION INFO.:	US 2002-114722	A1	20020402 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-710416, filed on 9 Nov 2000, GRANTED, Pat. No. US 6410645 Division of Ser. No. US 1996-692914, filed on 26 Jul 1996, GRANTED, Pat. No. US 6201065		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-1723P	19950728 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PATREA L. PABST, HOLLAND & KNIGHT LLP, SUITE 2000, ONE ATLANTIC CENTER, 1201 WEST PEACHTREE STREET, N.E., ATLANTA, GA, 30309-3400	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1480	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Gel-forming macromers including at least four polymeric
 blocks, at least two of which are hydrophobic and at least one of which
 is hydrophilic, and including a crosslinkable group are provided. The
 macromers can be covalently crosslinked to form a **gel** on a

tissue surface in vivo. The **gels** formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2002:152720 USPATFULL
TITLE: Multiblock biodegradable hydrogels for drug delivery and tissue treatment
INVENTOR(S): Pathak, Chandrashekhar P., Lexington, MA, United States
Barman, Shikha P., Bedford, MA, United States
Philbrook, C. Michael, Boston, MA, United States
Sawhney, Amarpreet S., Lexington, MA, United States
Coury, Arthur J., Boston, MA, United States
Avila, Luis Z., Arlington, MA, United States
Kieras, Mark T., Burlingame, CA, United States
PATENT ASSIGNEE(S): Focal, Inc., Lexington, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410645	B1	20020625
APPLICATION INFO.:	US 2000-710416		20001109 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-692914, filed on 26 Jul 1996, now patented, Pat. No. US 6201065		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-1723P	19950728 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Yoon, Tae H.	
LEGAL REPRESENTATIVE:	Holland & Knight LLP	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1392	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Gel**-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a **gel** on a tissue surface in vivo. The **gels** formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2001:36912 USPATFULL
TITLE: Multiblock biodegradable hydrogels for drug delivery and tissue treatment
INVENTOR(S): Pathak, Chandrashekhar P., Lexington, MA, United States
Barman, Shikha P., Bedford, MA, United States
Philbrook, C. Michael, Boston, MA, United States
Sawhney, Amarpreet S., Lexington, MA, United States
Coury, Arthur J., Boston, MA, United States
Avila, Luis Z., Arlington, MA, United States
Kieras, Mark T., Burlingame, CA, United States
PATENT ASSIGNEE(S): Focal, Inc., Lexington, MA, United States (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6201065	B1	20010313
APPLICATION INFO.:	US 1996-692914		19960726 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Yoon, Tae		
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory, LLP		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 8. Drawing Page(s)		
LINE COUNT:	1517		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a **gel** on a tissue surface in vivo. The **gels** formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 5 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2003:149942 EPFULL
ENTRY DATE PATENT: 20050223
ENTRY DATE PUBLICATION: 20050223
UPDATE DATE PUBLICAT.: 20050223
DATA UPDATE DATE: 20050223
DATA UPDATE WEEK: 200508
TITLE (ENGLISH): Wrapping material for seamless capsules
TITLE (FRENCH): Materiau d'enrobage pour **gelules** sans soudure
TITLE (GERMAN): Huellmaterial fuer nahtlose Kapseln
INVENTOR(S): Voigt, Ines, Reismuehle 20, 22087 Hamburg, DE;
Schleifenbaum, Birgit, Route de la Versoix 5, 1299
Crans pres Celigny, CH; Aickele, Frank, Weisse Breite
15, 37603 Holzminden, DE
PATENT APPLICANT(S): Symrise GmbH & Co. KG, Muehlenfeldstrasse 1, 37603
Holzminden, DE
PATENT APPL. NUMBER: 4476030
AGENT: Eisenfuehr, Guenther, Dipl.-Ing., Eisenfuehr, Speiser &
Partner Patentanwaelte Rechtsanwaelte Postfach 10 60
78, 28060 Bremen, DE
AGENT NUMBER: 3301
LANGUAGE OF FILING: German
LANGUAGE OF PUBL.: German
LANGUAGE OF PROCEDURE: German
LANGUAGE OF TITLE: German; English; French
DOCUMENT TYPE: Patent
PATENT INFO TYPE: EPA1 Application published with search report
PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES:	EP 1508591	A1	20050223
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI		
	LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2003-19044	A	20030822
PRIORITY INFO.:	EP 2003-19044	A	20030822 *

ABEN

Composition for use as a sheathing material for the production of seamless capsules comprises agar, a hydrolyzed starch having a viscosity of less than 50 mPas and water

A composition (I) for use as a sheathing material for the production of seamless capsules (II) comprising a liquid core and an encapsulating sheath comprises: (a) 1.5-4 weight% agar; (b) 10-22 weight% of a hydrolyzed starch having a viscosity of less than 50 mPas (measured as a 15 weight% aqueous solution at 80 degreesC); (c) 70-85 weight% water and optionally other additives. Independent claims are included for: (1) a seamless capsule (II) having a sheath comprising the composition (I); (2) a process for the production of the capsules (II) by preparation of a liquid core, preparation of the composition (I) with simultaneous extrusion of the core and composition (I) through inner and outer nozzles such that droplets having a liquid core and sheath form followed by hardening of the sheath with optional drying.